Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months -- New analyses evaluate the overall survival implications of both preserving body mass and reducing tumor volume -NEW YORK, Sept…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.